Fabian Lang, MD, Goethe University, Frankfurt, Germany, gives an overview of the results of a Phase I trial evaluating the safety and efficacy of asciminib in patients with chronic myeloid leukemia (CML) in the chronic phase carrying the T315I mutation (NCT02081378). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
